Senestech (SNES) Q2 2024 earnings summary

Executive summary

• Achieved record revenue of $874,000 in the first half of 2024, up 62% year-over-year, driven by the Evolve product line and operational improvements.

• Q2 2024 revenue reached $459,000, a 50% increase compared to Q2 2023, with net loss for Q2 2024 at $1.6 million, a 21% improvement from Q2 2023.

• Evolve, a fertility control product for rats, launched in January 2024, is now approved in 44 states and has shown strong efficacy in trials; Evolve Mouse, launched in May 2024, is available in 32 states.

• Expanded distribution and sales channels, including international agreements in 11 countries, agribusiness, pest management, retail, and e-commerce.

• Cash and cash equivalents stood at $2.0 million as of June 30, 2024, with an accumulated deficit of $133.3 million.

Financial highlights

• Q2 2024 revenue increased 50% year-over-year to $459,000; year-to-date revenue up 62% to $874,000.

• Gross margin for Q2 2024 was 54%, up from 47% in Q1 2024 and 46.4% in Q2 2023; June gross margin reached 67%.

• Evolve product line accounts for about 59–60% of total sales.

• Operating expenses for Q2 2024 were $1.85 million, down from $2.14 million in Q2 2023.

• Cash used in operations was $3.4 million for the first half of 2024, down from $3.8 million in the prior year period.

Outlook and guidance

• Management anticipates accelerating growth in the second half of 2024 due to new product launches, expanded distribution, and potential large retail orders.

• Placement by one or two major retailers could result in immediate profitability; optimism for near-term cash flow breakeven.

• Cash and anticipated revenue expected to fund operations for at least three months; additional capital will be needed to reach profitability.